Santiago Grau1, Esther Fondevilla2, Daniel Echeverría-Esnal3, Amaia Alcorta2, Enric Limon4, Francesc Gudiol5. 1. Member of the VINCat Committee, Department of Health, Catalonia, Spain; Pharmacy Department, Hospital Del Mar, Barcelona, Spain. Electronic address: sgrau@hospitaldelmar.cat. 2. VINCat Coordinating Centre, Feixa Llarga sn, Facultat de Medicina, Departament de Ciències Clíniques, Barcelona, Spain. 3. Pharmacy Department, Hospital Del Mar, Barcelona, Spain. 4. Coordinator of VINCat Program, Feixa Llarga sn, Facultat de Medicina, Departament de Ciències Clíniques, Barcelona, Spain. 5. Director of VINCat Program, Feixa Llarga sn, Facultat de Medicina, Departament de Ciències Clíniques, Barcelona, Spain; IDIBELL, University of Barcelona, Spain.
Abstract
INTRODUCTION: The overall increase in the use of carbapenems could lead to the selection of carbapenem-resistant bacteria. The objectives of this study were to analyze carbapenem use from 2008 to 2015 and their prescription profile in 58 hospitals affiliated to the VINCat Programme (nosocomial infection vigilance system). METHODS: Retrospective, longitudinal and descriptive study of carbapenem use. Consecutive case-series study, looking for carbapenem prescription characteristics, conducted in January 2016. Use was calculated in defined daily doses (DDD)/100 patient-days (PD); prescription profiles were assessed using a standardized survey. RESULTS: Carbapenem use increased 88.43%, from 3.37 DDD/100-PD to 6.35 DDD/100-PD (p<0.001). A total of 631 patients were included in the prescription analysis. Carbapenems were prescribed empirically in 76.2% of patients, mainly for urinary tract and intra-abdominal infections due to suspicion of polymicrobial mixed infection (27.4%) and severity (25.4%). CONCLUSION: A worrying increase in carbapenem use was found in Catalonia. Stewardship interventions are required to prevent carbapenem overuse.
INTRODUCTION: The overall increase in the use of carbapenems could lead to the selection of carbapenem-resistant bacteria. The objectives of this study were to analyze carbapenem use from 2008 to 2015 and their prescription profile in 58 hospitals affiliated to the VINCat Programme (nosocomial infection vigilance system). METHODS: Retrospective, longitudinal and descriptive study of carbapenem use. Consecutive case-series study, looking for carbapenem prescription characteristics, conducted in January 2016. Use was calculated in defined daily doses (DDD)/100 patient-days (PD); prescription profiles were assessed using a standardized survey. RESULTS:Carbapenem use increased 88.43%, from 3.37 DDD/100-PD to 6.35 DDD/100-PD (p<0.001). A total of 631 patients were included in the prescription analysis. Carbapenems were prescribed empirically in 76.2% of patients, mainly for urinary tract and intra-abdominal infections due to suspicion of polymicrobial mixed infection (27.4%) and severity (25.4%). CONCLUSION: A worrying increase in carbapenem use was found in Catalonia. Stewardship interventions are required to prevent carbapenem overuse.
Keywords:
BLEE; Carbapenemas; Carbapenems; ESBL; Programas de optimización de uso de antimicrobianos (PROA); Programs for optimizing the use of antibiotics (PROA); Use of antimicrobials; Uso de antimicrobianos
Authors: Josep M Badia; Maria Batlle; Montserrat Juvany; Patricia Ruiz-de León; Maria Sagalés; M Angeles Pulido; Gemma Molist; Jordi Cuquet Journal: Antibiotics (Basel) Date: 2020-12-24
Authors: Mario Rivera-Izquierdo; Antonio Jesús Láinez-Ramos-Bossini; Carlos Rivera-Izquierdo; Jairo López-Gómez; Nicolás Francisco Fernández-Martínez; Pablo Redruello-Guerrero; Luis Miguel Martín-delosReyes; Virginia Martínez-Ruiz; Elena Moreno-Roldán; Eladio Jiménez-Mejías Journal: Antibiotics (Basel) Date: 2021-01-18